Concepedia

Paul Handley

PH

Statistics

Publications

9

Citations

563

H-Index

9

Active since

1999

Affiliations

The University of Queensland(Current)

Griffith University

Ligand Pharmaceuticals (United Kingdom)

University of Newcastle Australia

Duke Medical Center

Paul Handley is an author at The University of Queensland specializing in life sciences, glycan structure, and pharmacology.

Publications per year

1999–2018

9

Publications

9

PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models

Keith Dredge, Edward Hammond, Paul Handley et al. · British Journal of Cancer · 2011 · 165 citations · Full text

, , +17

Discovery of PG545: A Highly Potent and Simultaneous Inhibitor of Angiogenesis, Tumor Growth, and Metastasis

Vito Ferro, Ligong Liu, Ken D. Johnstone et al. · Journal of Medicinal Chemistry · 2012 · 131 citations · Full text

, , +16

A Phase I study of the novel immunomodulatory agent PG545 (pixatimod) in subjects with advanced solid tumours

Keith Dredge, Todd V. Brennan, Edward Hammond et al. · British Journal of Cancer · 2018 · 100 citations · Full text

, , +17

Mechanisms of heparanase inhibition by the heparan sulfate mimetic PG545 and three structural analogues

Edward Hammond, Paul Handley, Keith Dredge et al. · FEBS Open Bio · 2013 · 59 citations · Full text

, , +17

Immunomodulatory activities of pixatimod: emerging nonclinical and clinical data, and its potential utility in combination with PD-1 inhibitors

Edward Hammond, Nicole M. Haynes, Carleen Cullinane et al. · Journal for ImmunoTherapy of Cancer · 2018 · 49 citations · Full text

, , +17

1–5 of 9